Tin tức & Cập nhật

Latest findings from the ongoing phase III NATALEE trial have shown that 3-year treatment with adjuvant ribociclib, in combination with a nonsteroidal aromatase inhibitor (NSAI), remained well tolerated in patients with HR+/HER2- early-stage breast cancer (EBC).

Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date. 

Fludarabine, melphalan, and total marrow irradiation (TMI) 900 cGy may be utilized as conditioning for allogeneic stem cell transplantation in patients with high-risk or relapsed/refractory multiple myeloma, as shown in a phase I trial.

A nomogram model displays a decent performance in predicting grade ≥2 acute radiation enteritis (ARE) among patients with cervical cancer receiving concurrent chemoradiotherapy, a study has shown.

Systemic and intrathecal therapies are necessary for local control in patients with primary central nervous system lymphoma (PCNSL), but bulky tumours remain a problem, according to a study.